Welcome!
Eddy Lee
Healthcare
iX Biopharma inks exclusive agreement with Seelos worth up US$239 mil
iX Biopharma will also receive double digit percentage royalties on future net sales of any licensed product.
November 24, 2021
In print this week
Pharma developer iX Biopharma banks on online supplement sales for growth, profits
SINGAPORE (Dec 18): Catalist-listed iX Biopharma has launched a line of nutraceuticals that could help it turn a profit sooner than it could have done through the development of its pain management, erectile dysfunction and opioid treatment drugs. The pro
December 18, 2017
In print this week
Why are investors cool to the stocks of these two innovative medtech firms?
SINGAPORE (Aug 26): iX Biopharma is a small Catalist-listed Singapore company focusing on a big goal: Developing pain management drugs that are an alternative to opioids, and the optimum system to deliver these drugs into the body.
August 26, 2016